Stocks · News reference
William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Tango Therapeutics announced it will present updated Phase 1/2 study data on vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP-deleted RAS-mutant metastatic pancreatic and lung cancers at the ESMO Congress 2026 in Madrid. The company will also host a PDAC-focused investor webcast on October 23, 2026.
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present
Tango Therapeutics (TNGX) stock has declined 6.2% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a wider-than-expected loss of 37 cents per share due to higher operating expenses, with R&D expenses up 13% and G&A expenses nearly doubling. Collaboration revenues dropped to zero from $3.2 million year-over-year following the conclusion of its Gilead partnership. Analyst estimates have shifted downward by 10.16% in the past month, and the stock carries a Zacks Rank #3 (Hold) with poor VGM scores across growth, momentum, and value metrics.